Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)

NCT03334864 | Unknown

• 1 other identifier: JS-1410
• Study Type: observational
• Target: 5,000
• Locations: 1 country
• Sites: 1

Brief Summary

Investigators propose to establish and maintain a cohort of patients with advanced non-small cell lung cancer, and to assess the treatment pattern, host genetic, and clinical factors which influence the prognosis and survival, as well as the interaction among these factors on disease diagnosis and treatment, short and long-term outcomes. Study type: Observational (Patient Registry) Study design: Observational Model: Cohort Time Perspective: Prospective and retrospective

Conditions

Advanced Non-small Cell Lung Cancer

Keywords

Advanced non-small cell lung cancer

Outcome Measures

Primary Outcomes (1)

• Overall Survival (OS)

  OS was calculated from the diagnosis of advanced non-small cell lung cancer to death from any reasons

  3 years

Study Arms (5)

I Retrospective cohort

Diagnosis of advanced non-small cell lung cancer from 2012-2016

II Prospective cohort

Advanced non-small cell lung cancer with driver gene mutations

III Prospective cohort

Non-small cell lung cancer in immuno-therapy;

IV Prospective cohort

Non-small cell lung cancer with wild-type driver gene or unknown driver gene status;

V Prospective cohort

Advanced non-small lung cancer with wild-type gene treated with anti-Vascular Endothelial Growth Factor (VEGF) drug.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

5000 advanced NSCLC patients

You may qualify if:

• Cohort I: diagnosis of advanced non-small cell lung cancer from 2012-2016;
• Cohort II: documented positive driver gene mutations; and diagnosis of advanced non-small cell lung cancer;
• Cohort III: diagnosis of advanced non-small cell lung cancer and in immune-therapy;
• Cohort IV: diagnosis of advanced non-small cell lung cancer, and with wild-type driver gene or unknown driver gene status;
• Cohort V: treated with anti-VEGF drug in first line, diagnosis of advanced non-squamous and non-small cell lung cancer in 6 months before recruit;
• Age\>18 years;
• Provision of written informed consent.

You may not qualify if:

• not applicable

Sponsors & Collaborators

• Peking Union Medical College Hospital: lead

Study Sites (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

RECRUITING

Related Publications (1)

• Xu Y, Zhang L, Fang J, Wang Z, Li J, Li L, Ai B, Nie L, Mu X, Liang L, Zhang S, Zhang Y, Song Y, Song X, Wang Y, Xin T, Jin B, Wang X, Ding C, Wang M. Establishment of a prospective multicenter cohort for advanced non-small cell lung cancer in China (CAPTRA-Lung study). Thorac Cancer. 2018 Dec;9(12):1795-1800. doi: 10.1111/1759-7714.12865. Epub 2018 Sep 27.

  PMID: 30264504 DERIVED

Central Study Contacts

Yan Xu, M.D.

CONTACT

861069155039; maraxu@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Target Duration: 3 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 31, 2017
• First Posted: November 7, 2017
• Study Start: November 3, 2022
• Primary Completion: December 1, 2025
• Study Completion: December 1, 2025
• Last Updated: September 11, 2023

Record last verified: 2022-11

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)